Ovarian Hyperstimulation Syndrome: Clinical Trials

15 trials for Ovarian Hyperstimulation Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 5 unknown, 3 terminated. 15 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 415Completed 7, Unknown 5, Terminated 3

Follow Ovarian Hyperstimulation Syndrome: new trials by email Literature Review of Ovarian Hyperstimulation Syndrome trials Research Report on Ovarian Hyperstimulation Syndrome

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS
Gonadotropin, Antagonist - Ovarian Hyperstimulation Syndrome
Phase 4CompletedClinAmygate3002019-07-012019-11-21
Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome
Pregnyl (1,500) IU, 1.5 mL of normal saline - Ovarian Hyperstimulation Syndrome, Infertility, Female
Phase 4UnknownMount Sinai Hospital, Canada802019-05-012023-07-03
Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders
Synarel, 0.2 Mg/Inh Nasal Spray, Estrofem, Utrogestan - Pregnancy Early, Miscarriage
Phase 4UnknownAssaf-Harofeh Medical Center1002017-12-292021-04-01
Preventive Application of GnRH Antagonist on Early OHSS
GnRH antagonist, aspirin - Ovarian Hyperstimulation Syndrome, GnRH Antagonist
Phase 4UnknownFirst Affiliated Hospital, Sun Yat-Sen University1752017-01-012017-06-15
Corifollitropin Alfa Application in PCOS Patients
Corifollitropin alfa - In Vitro Fertilization
Phase 4UnknownShin Kong Wu Ho-Su Memorial Hospital302014-01-012014-08-13
Low-dose Gonal-f® in Ovulation Induction
Gonal-f® - Infertility, Monofollicular Development
Phase 4TerminatedMerck KGaA, Darmstadt, Germany242013-07-012016-08-11
Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
hCG - Ovarian Hyperstimulation Syndrome
Phase 4CompletedUConn Health892013-03-012018-10-26
Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?
Triptorelin 0.2 mg - Ovarian Hyperstimulation Syndrome
Phase 4TerminatedElisha Hospital62012-11-012015-08-04
Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation
GnRH agonist, hCG - Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Phase 4TerminatedUConn Health72012-04-012018-11-21
Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS
letrozole, Aspirin - Ovarian Hyperstimulation Syndrome
Phase 4CompletedFirst Affiliated Hospital, Sun Yat-Sen University1002012-01-012016-02-01
Endometrial Receptivity After GnRH Agonist Triggering
hCG, triptorelin, Triptorelin, estradiol valerate, micronized vaginal progesterone - Ovarian Hyperstimulation Syndrome
Phase 4CompletedIVI Madrid352011-11-012016-10-26
Short Versus Long Protocol for IVF and IVF+ICSI
Patients receiving short protocol IVF/ICSI-treatment., Long protocol - Infertility, Ovarian Hyperstimulation Syndrome
Phase 4CompletedPeter Hornnes, MD, DMSc10992009-01-012016-01-13
Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles
Buserelin and Pregnyl, Pregnyl - OHSS (Ovarian Hyperstimulation)
Phase 4CompletedRegionshospitalet Viborg, Skive3842009-01-012013-11-27
The Use of GnRH Agonist Trigger in the Prevention of OHSS
Leuprolide acetate - Ovarian Hyperstimulation Syndrome
Phase 4CompletedUniversity of Connecticut662004-08-012006-07-06
Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients
Arvekap 0.1mg (Triptorelin, Ipsen, France), Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands) - Polycystic Ovary Syndrome, Ovarian Hyperstimulation Syndrome
Phase 4UnknownEugonia2002003-11-012006-12-29

Narrower conditions

Polycystic Ovary Syndrome (3)  ·  Infertility (2)  ·  Abortion, Spontaneous (1)  ·  Infertility, Female (1)

Broader conditions

Adnexal Diseases (15)  ·  Endocrine System Diseases (15)  ·  Female Urogenital Diseases (15)  ·  Female Urogenital Diseases and Pregnancy Complications (15)  ·  Genital Diseases (15)  ·  Genital Diseases, Female (15)  ·  Gonadal Disorders (15)  ·  Ovarian Diseases (15)  ·  Urogenital Diseases (15)  ·  Cysts (3)  ·  Neoplasms (3)  ·  Ovarian Cysts (3)  ·  Infertility (1)  ·  Pregnancy Complications (1)

Interventions

Chorionic Gonadotropin (4)  ·  Triptorelin Pamoate (3)  ·  Aspirin (2)  ·  Estradiol (2)  ·  Leuprolide (2)  ·  17 alpha-Hydroxyprogesterone Caproate (1)  ·  Buserelin (1)  ·  Glycoprotein Hormones, alpha Subunit (1)  ·  Gonadotropin-Releasing Hormone (1)  ·  Gonadotropins (1)  ·  LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- (1)  ·  Letrozole (1)  ·  Nafarelin (1)  ·  Profasi (1)  ·  Progesterone (1)

Sponsors

First Affiliated Hospital, Sun Yat-Sen University (2)  ·  UConn Health (2)  ·  Assaf-Harofeh Medical Center (1)  ·  ClinAmygate (1)  ·  Elisha Hospital (1)  ·  Eugonia (1)  ·  IVI Madrid (1)  ·  Merck KGaA, Darmstadt, Germany (1)  ·  Mount Sinai Hospital, Canada (1)  ·  Peter Hornnes, MD, DMSc (1)  ·  Regionshospitalet Viborg, Skive (1)  ·  Shin Kong Wu Ho-Su Memorial Hospital (1)  ·  University of Connecticut (1)

Countries

United States (3)  ·  Denmark (2)  ·  Israel (2)  ·  Canada (1)  ·  China (1)  ·  Egypt (1)  ·  Greece (1)  ·  Ireland (1)  ·  Spain (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Lawrence Engmann, MD (2)  ·  Alfonso Bermejo, MD (1)  ·  Claudio Benadiva, MD (1)  ·  Eman Elgendy, MD (1)  ·  Helle Meinertz (1)  ·  Jiann-Loung Hwang, MD (1)  ·  Lawrence Engmann, MD, MRCOG (1)  ·  Michal Youngster, MD (1)  ·  Miguel Russo, MD (1)  ·  Peter Hornnes (1)  ·  Peter S Humaidan, MD (1)  ·  Qingyun Mai (1)  ·  Shahar Kol, MD (1)  ·  Thue Bryndorf (1)

Results publications

PMID 17854523, PMID 20008886, PMID 21601197, PMID 23753114, PMID 27060174, PMID 28130435, PMID 29175067, PMID 31227286